September 20, 2024
TOPLINE: Compared with placebo, ubrogepant 100 mg taken during the prodrome phase of a migraine attack significantly improves normal functioning and reduces activity limitations over 24 […]
September 20, 2024
COPENHAGEN, Denmark — High-dose oral cholecalciferol (vitamin D3) supplementation significantly reduces evidence of disease activity in patients with clinically isolated syndrome (CIS), results of a randomized, […]
September 19, 2024
Four triptans are more effective for acute migraine than newer, more expensive medications for this headache type, new research suggested. Results of a large systematic review […]
September 17, 2024
TOPLINE: Having an untreated unruptured intracranial aneurysm (UIA) was associated with a 10% higher risk of mental illness than not having a UIA, especially among younger […]
September 16, 2024
Researchers have developed a blood test for amyotrophic lateral sclerosis (ALS) that could lead to more rapid and accurate diagnosis when used alongside standard clinical evaluations. […]
September 13, 2024
The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of the anti-CD20 antibody ocrelizumab (Ocrevus Zunovo, Genentech) for the treatment of relapsing multiple […]
September 13, 2024
TOPLINE: Amyloid pathology typical of Alzheimer’s disease (AD) is 50% lower in patients with multiple sclerosis (MS) than in those without the condition, an analysis of […]
September 10, 2024
TOPLINE: Dementia in Parkinson’s disease (PD) may occur less frequently or develop over a longer period than previously thought, an analysis of two studies suggests. Increasing […]
September 9, 2024
Postoperative cognitive dysfunction (POCD) is a form of cognitive decline that involves a functional deterioration of activities of the nervous system, such as selective attention, vigilance, […]